241 related articles for article (PubMed ID: 28032662)
1. 5-Hydroxymethylcytosine is a nuclear biomarker to assess biological potential in histologically ambiguous heavily pigmented melanocytic neoplasms.
Lee JJ; Vilain RE; Granter SR; Hu NR; Bresler SC; Xu S; Frank AH; Mihm MC; Saw RP; Fletcher CD; Scolyer RA; Murphy GF; Lian CG
J Cutan Pathol; 2017 Mar; 44(3):249-255. PubMed ID: 28032662
[TBL] [Abstract][Full Text] [Related]
2. Diagnostic utility of dual 5-hydroxymethylcytosine/Melan-A immunohistochemistry in differentiating nodal nevus from metastatic melanoma: An effective first-line test for the workup of sentinel lymph node specimen.
Siref AB; Huynh CAT; Balzer BL; Frishberg DP; Essner R; Shon W
J Cutan Pathol; 2019 Apr; 46(4):261-266. PubMed ID: 30632191
[TBL] [Abstract][Full Text] [Related]
3. β-Catenin nuclear expression discriminates deep penetrating nevi from other cutaneous melanocytic tumors.
de la Fouchardière A; Caillot C; Jacquemus J; Durieux E; Houlier A; Haddad V; Pissaloux D
Virchows Arch; 2019 May; 474(5):539-550. PubMed ID: 30756182
[TBL] [Abstract][Full Text] [Related]
4. Loss of expression of protein kinase a regulatory subunit 1alpha in pigmented epithelioid melanocytoma but not in melanoma or other melanocytic lesions.
Zembowicz A; Knoepp SM; Bei T; Stergiopoulos S; Eng C; Mihm MC; Stratakis CA
Am J Surg Pathol; 2007 Nov; 31(11):1764-75. PubMed ID: 18059235
[TBL] [Abstract][Full Text] [Related]
5. 5-Hydroxymethylcytosine Expression in Proliferative Nodules Arising within Congenital Nevi Allows Differentiation from Malignant Melanoma.
Pavlova O; Fraitag S; Hohl D
J Invest Dermatol; 2016 Dec; 136(12):2453-2461. PubMed ID: 27456754
[TBL] [Abstract][Full Text] [Related]
6. Diagnostic Utility of LEF1 Immunohistochemistry in Differentiating Deep Penetrating Nevi From Histologic Mimics.
Raghavan SS; Saleem A; Wang JY; Rieger KE; Brown RA; Novoa RA
Am J Surg Pathol; 2020 Oct; 44(10):1413-1418. PubMed ID: 32520758
[TBL] [Abstract][Full Text] [Related]
7. Pigmented epithelioid melanocytoma: a low-grade melanocytic tumor with metastatic potential indistinguishable from animal-type melanoma and epithelioid blue nevus.
Zembowicz A; Carney JA; Mihm MC
Am J Surg Pathol; 2004 Jan; 28(1):31-40. PubMed ID: 14707861
[TBL] [Abstract][Full Text] [Related]
8. CYSLTR2-mutant Cutaneous Melanocytic Neoplasms Frequently Simulate "Pigmented Epithelioid Melanocytoma," Expanding the Morphologic Spectrum of Blue Tumors: A Clinicopathologic Study of 7 Cases.
Goto K; Pissaloux D; Paindavoine S; Tirode F; de la Fouchardière A
Am J Surg Pathol; 2019 Oct; 43(10):1368-1376. PubMed ID: 31162285
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic utility of 5-hydroxymethylcytosine immunohistochemistry in melanocytic proliferations.
Rodić N; Zampella J; Sharma R; Burns KH; Taube JM
J Cutan Pathol; 2015 Nov; 42(11):807-14. PubMed ID: 26239102
[TBL] [Abstract][Full Text] [Related]
10. 5-Hydroxymethylcytosine as a useful marker to differentiate between malignant melanomas and benign melanocytic nevi.
Uchiyama R; Uhara H; Uchiyama A; Ogawa E; Takazawa Y; Ashida A; Koga H; Hayashi K; Kiniwa Y; Okuyama R
J Dermatol Sci; 2014 Feb; 73(2):161-3. PubMed ID: 24169492
[No Abstract] [Full Text] [Related]
11. Clinical and Histopathologic Characteristics of Melanocytic Lesions on the Volar Skin Without Typical Dermoscopic Patterns.
Mikoshiba Y; Minagawa A; Koga H; Yokokawa Y; Uhara H; Okuyama R
JAMA Dermatol; 2019 May; 155(5):578-584. PubMed ID: 30865233
[TBL] [Abstract][Full Text] [Related]
12. Deep penetrating nevus-like borderline tumors: A unique subset of ambiguous melanocytic tumors with malignant potential and normal cytogenetics.
Magro CM; Abraham RM; Guo R; Li S; Wang X; Proper S; Crowson AN; Mihm M
Eur J Dermatol; 2014; 24(5):594-602. PubMed ID: 25118781
[TBL] [Abstract][Full Text] [Related]
13. Combined melanocytic nevi: histologic variants and melanoma mimics.
Baran JL; Duncan LM
Am J Surg Pathol; 2011 Oct; 35(10):1540-8. PubMed ID: 21881487
[TBL] [Abstract][Full Text] [Related]
14. PRAME immunohistochemistry is useful in the evaluation of conjunctival melanomas, nevi, and primary acquired melanosis.
LeBlanc RE; Miller DM; Zegans ME
J Cutan Pathol; 2021 Dec; 48(12):1442-1448. PubMed ID: 34089198
[TBL] [Abstract][Full Text] [Related]
15. Comparison of Immunohistochemistry for PRAME With Cytogenetic Test Results in the Evaluation of Challenging Melanocytic Tumors.
Lezcano C; Jungbluth AA; Busam KJ
Am J Surg Pathol; 2020 Jul; 44(7):893-900. PubMed ID: 32317605
[TBL] [Abstract][Full Text] [Related]
16. Loss of the epigenetic mark, 5-Hydroxymethylcytosine, correlates with small cell/nevoid subpopulations and assists in microstaging of human melanoma.
Lee JJ; Cook M; Mihm MC; Xu S; Zhan Q; Wang TJ; Murphy GF; Lian CG
Oncotarget; 2015 Nov; 6(35):37995-8004. PubMed ID: 26462027
[TBL] [Abstract][Full Text] [Related]
17. Rate of Immunohistochemistry Utilization in the Diagnosis of Cutaneous Melanocytic Lesions.
Chen TC; Hitchcock MG
Am J Dermatopathol; 2021 Dec; 43(12):e146-e148. PubMed ID: 33795556
[TBL] [Abstract][Full Text] [Related]
18. Comparison of pHH3, Ki-67, and survivin immunoreactivity in benign and malignant melanocytic lesions.
Nasr MR; El-Zammar O
Am J Dermatopathol; 2008 Apr; 30(2):117-22. PubMed ID: 18360113
[TBL] [Abstract][Full Text] [Related]
19. Loss of 5-hydroxymethylcytosine correlates with increasing morphologic dysplasia in melanocytic tumors.
Larson AR; Dresser KA; Zhan Q; Lezcano C; Woda BA; Yosufi B; Thompson JF; Scolyer RA; Mihm MC; Shi YG; Murphy GF; Lian CG
Mod Pathol; 2014 Jul; 27(7):936-44. PubMed ID: 24390216
[TBL] [Abstract][Full Text] [Related]
20. PRAME Expression in Melanocytic Tumors.
Lezcano C; Jungbluth AA; Nehal KS; Hollmann TJ; Busam KJ
Am J Surg Pathol; 2018 Nov; 42(11):1456-1465. PubMed ID: 30045064
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
